Akeso

Harbin, Heilongjiang

Oncologygene editingPhase IListed · 9926.HK

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: High-flow Nasal Cannula Versus Conventional Oxygen During Awake Tracheal Intubation With Difficult Airways

5w agoTrial registeredJun 10, 2026Source filing (opens the source filing in a new tab)

Momentum

82no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
NA registered
Feb 4, 2026
Awake Tracheal Intubation, Difficult Airway · RECRUITING · sponsor: Wenxian Li · High-flow Nasal Cannula Versus Conventional Oxygen During Awake Tracheal Intubation With Difficult Airways
ClinicalTrials.gov · NCT07384494 (opens the source filing in a new tab)
Trial
PHASE1 registered
Oct 22, 2025
Solid Cancer · RECRUITING · sponsor: Akeso · A Study of AK138D1 in Advanced Malignant Tumors
ClinicalTrials.gov · NCT07281326 (opens the source filing in a new tab)
Grant
R03 · $160k · non-dilutive
Jul 1, 2025
UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LI, WILLIS X · NCI · award ends Jun 30, 2027 · Role of STAT in heterochromatin initiation
NIH RePORTER · NIH RePORTER 11121531 (opens the source filing in a new tab)
Grant
R01 · $568k · non-dilutive
Jul 1, 2025
BAYLOR COLLEGE OF MEDICINE · PI LI, WEI · NEI · award ends Mar 31, 2030 · The role of vascular ligands and neurovascular dysfunction in glaucoma and therapeutic potential
NIH RePORTER · NIH RePORTER 11102831 (opens the source filing in a new tab)
Grant
R01 · $440k · non-dilutive
Jun 3, 2024
MAYO CLINIC ARIZONA · PI BHAT, KRISHNA PL · NINDS · award ends May 31, 2028 · Novel Roles of TAZ and YAP in DNA Damage Repair with 3D Genome Organization and the Therapeutic Resistance in Glioblastoma
NIH RePORTER · NIH RePORTER 11145285 (opens the source filing in a new tab)
Grant
R01 · $677k · non-dilutive
Jul 28, 2023
NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SULMAN, ERIK · NCI · award ends Jun 30, 2028 · Exploiting cell fate transition to overcome radiation resistance in glioblastoma
NIH RePORTER · NIH RePORTER 11124133 (opens the source filing in a new tab)
Grant
R01 · $345k · non-dilutive
Jan 1, 2023
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LI, WEN · NIMH · award ends Oct 31, 2027 · A Neurosensory Account of Posttraumatic Stress Disorder
NIH RePORTER · NIH RePORTER 11184994 (opens the source filing in a new tab)
Grant
R01 · $563k · non-dilutive
Jul 6, 2022
WASHINGTON UNIVERSITY · PI SCHUETTPELZ, LAURA G. · NIAID · award ends Jun 30, 2027 · Defining the partner interaction network of the tetraspanin CD53 in regulating B cell trafficking
NIH RePORTER · NIH RePORTER 11116852 (opens the source filing in a new tab)
Grant
P01 · $203k · non-dilutive
May 12, 2015
WASHINGTON UNIVERSITY · PI LI, WENJUN · NIAID · award ends May 31, 2030 · Microsurgery Core
NIH RePORTER · NIH RePORTER 11112100 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 77%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Study registered, no phase assigned: High-flow Nasal Cannula Versus Conventional Oxygen During Awake Tracheal Intubation With Difficult Airways
5w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: High-flow Nasal Cannula Versus Conventional Oxygen During Awake Tracheal Intubation With Difficult Airways
5w agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Study of AK138D1 in Advanced Malignant Tumors
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of AK138D1 in Advanced Malignant Tumors
7mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Defining the partner interaction network of the tetraspanin CD53 in regulating B cell trafficking
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R03 · $0.2M · Role of STAT in heterochromatin initiation
Jun 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Exploiting cell fate transition to overcome radiation resistance in glioblastoma
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · The role of vascular ligands and neurovascular dysfunction in glaucoma and therapeutic potential
Jun 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Novel Roles of TAZ and YAP in DNA Damage Repair with 3D Genome Organization and the Therapeutic Resistance in Glioblastoma
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH P01 · $0.2M · Microsurgery Core
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · A Neurosensory Account of Posttraumatic Stress Disorder
Apr 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

NA registered

PHASE1 registered

R03 · $160k · non-dilutive

R01 · $568k · non-dilutive

R01 · $440k · non-dilutive

R01 · $677k · non-dilutive

R01 · $345k · non-dilutive

R01 · $563k · non-dilutive

P01 · $203k · non-dilutive